NovoCure Limited
NVCR
$15.23
$0.030.20%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 5.47% | -0.17% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 5.47% | -0.17% | |||
| Cost of Revenue | 5.59% | -3.75% | |||
| Gross Profit | 5.44% | 0.91% | |||
| SG&A Expenses | -29.55% | 30.88% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -19.60% | 14.15% | |||
| Operating Income | 84.33% | -81.32% | |||
| Income Before Tax | 82.02% | -69.11% | |||
| Income Tax Expenses | 70.53% | 111.43% | |||
| Earnings from Continuing Operations | 77.99% | -190.37% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 77.99% | -190.37% | |||
| EBIT | 84.33% | -81.32% | |||
| EBITDA | 90.12% | -83.55% | |||
| EPS Basic | 78.34% | -185.48% | |||
| Normalized Basic EPS | 82.30% | -5.36% | |||
| EPS Diluted | 78.34% | -185.48% | |||
| Normalized Diluted EPS | 82.30% | -5.36% | |||
| Average Basic Shares Outstanding | 1.63% | 1.70% | |||
| Average Diluted Shares Outstanding | 1.63% | 1.70% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||